Schering Jumps On Organon Buy; Will Late-Stage M&A Keep Fueling Pharma?
Pharmaceutical companies unveiling mergers and acquisitions in the first quarter were among those rewarded by Wall Street
You may also be interested in...
The full impact of Schering-Plough's deepening woes after a scientific panel's negative analysis of the Vytorin ENHANCE trial will not be known for a while, and some analysts predict there could be repercussions beyond the company and its joint venture with Merck, a deal centered on the anti-cholesterol drug, which combines the statin Zocor (simvastatin) withZetia (ezetimibe)
Schering-Plough sees significant growth potential for Organon's products that currently are marketed in the U.S., CEO Fred Hassan said March 20
Sanofi-Aventis' merger and acquisition efforts will focus on biotech firms and Japanese companies, CEO Gerard Le Fur maintained Feb. 13